VBI Vaccines (VBIV) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
VBI Vaccines Inc. has entered restructuring proceedings under the CCAA to explore strategic alternatives after a financial review. The company secured initial court protection and intends to facilitate a sale through a court-approved process while seeking support from U.S. and Israeli courts for its subsidiaries. VBI’s common shares are expected to stop trading on Nasdaq as the company transitions away from public reporting.
For further insights into VBIV stock, check out TipRanks’ Stock Analysis page.